Related Experiment Video
Updated: Jun 16, 2026
07:38
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Secondary acute myeloid leukemia - a single center experience
T Szotkowski1, P Rohon, L Zapletalova
1Department of Hemato-Oncology, Faculty of Medicine, Palacký University Olomouc, University Hospital Olomouc, Olomouc, Czech Republic. tszotkowski@seznam.cz
Neoplasma
|January 27, 2010
Summary
Secondary acute myeloid leukemia (sAML) has a poor prognosis and is rarely curable. This study analyzed 574 AML cases, finding sAML patients are older, have worse outcomes, and lower remission rates than primary AML.
Area of Science:
- Hematology
- Oncology
- Cancer Research
Background:
- Secondary acute myeloid leukemia (sAML) originates from prior hematologic disorders (myelodysplastic syndrome, chronic myeloproliferative neoplasia) or exposure to leukemogenic agents.
- sAML is associated with a poorer prognosis and is generally not considered curable, except for secondary acute promyelocytic leukemia.
Purpose of the Study:
- To analyze the characteristics and outcomes of patients with secondary acute myeloid leukemia.
- To compare sAML patients with those diagnosed with primary AML.
Main Methods:
- Retrospective analysis of 574 patients diagnosed with AML between 1996-2008.
- Categorization of AML cases into primary AML, sAML transformed from myelodysplastic syndrome, and sAML from other causes (malignancies or non-malignant disorders treated with leukemogenic agents).
Main Results:
- Out of 574 AML patients, 86 had sAML transformed from myelodysplastic syndrome and 58 had sAML from other causes.
- Patients with sAML were older and less likely to receive curative treatment compared to primary AML patients.
- sAML patients exhibited worse cytogenetic findings, lower complete remission rates, frequent relapses, and poorer overall survival across most prognostic subgroups.
Conclusions:
- Secondary acute myeloid leukemia generally carries an unfavorable prognosis and is not conventionally curable, with the exception of secondary acute promyelocytic leukemia.
- Treatment strategies and prognostic assessments for sAML should consider its distinct characteristics compared to primary AML.
